Coste Catherine has filed 8 insider transactions across 3 companies since January 2023.
Most recent transaction: a grant/award of 8170 shares of BIOLIFE SOLUTIONS INC ($BLFS) on February 24, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 24, 2026 | BIOLIFE SOLUTIONS INC | $BLFS | Coste Catherine | Director | A | Common Stock | 8170 | $0.00 | 13,871.0000 | 48,723,535 | 143.31% | 0.02% |
| March 18, 2025 | BIOLIFE SOLUTIONS INC | $BLFS | Coste Catherine | Director | A | Common Stock | 5701 | $0.00 | 5,701.0000 | 46,067,073 | 9999.99% | 0.01% |
| Dec. 13, 2024 | BIOMERICA INC | $BMRA | Coste Catherine | Director | A | Common stock | 85000 | $0.31 | 128,790.0000 | 0 | 194.11% | 0.00% |
| Dec. 13, 2023 | BIOMERICA INC | $BMRA | Coste Catherine | Director | A | Non-qualified stock option | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| April 20, 2023 | BIOMERICA INC | $BMRA | Coste Catherine | Director | A | Non-qualified stock option | 32000 | $0.00 | 32,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 20, 2023 | Renalytix plc | $RENXF | Coste Catherine | Director | A | Employee Stock Option (right to buy) | 95000 | $0.00 | 95,000.0000 | 0 | 9999.99% | 0.00% |
| July 6, 2023 | Renalytix plc | $RENXF | Coste Catherine | Director | A | Employee Stock Option (right to buy) | 190000 | $0.00 | 190,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 26, 2023 | BIOMERICA INC | $BMRA | Coste Catherine | Other | P | Common Stock | 2190 | $2.96 | 43,790.0000 | 0 | 5.26% | 0.00% |